<strong>Objective</strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:""> <i><span style="font-...<strong>Objective</strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:""> <i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;"> is the most common pathway affected by mutations in breast cancer. </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN pathway is under intense investigation as a possible target for molecular therapy. Dysregulation </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN pathway is a substantial mechanism for the development of resistance to anti-HER2 therapy. Therefore, we aimed to study the </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN in breast cancer patients in </span><span style="font-family:Verdana;">Saudi</span><span style="font-family:Verdana;"> population. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> We applied PTEN immunohistochemistry on 98 patients. Then, we applied next-generation sequencing to determine the genetic variations associated with the development of breast cancer and their correlations with clinicopathological variables. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">PTEN expression was significantly correlated with lymph node metastasis (LNM), tumor stage, lymphovascular invasion (LVI) </span><span style="font-family:Verdana;">and</span> <span style="font-family:Verdana;">triple negative</span><span style="font-family:展开更多
文摘<strong>Objective</strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:""> <i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;"> is the most common pathway affected by mutations in breast cancer. </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN pathway is under intense investigation as a possible target for molecular therapy. Dysregulation </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN pathway is a substantial mechanism for the development of resistance to anti-HER2 therapy. Therefore, we aimed to study the </span><i><span style="font-family:Verdana;">PIK</span></i><span><span style="font-family:Verdana;">3</span><i><span style="font-family:Verdana;">CA</span></i></span><span style="font-family:Verdana;">/PTEN in breast cancer patients in </span><span style="font-family:Verdana;">Saudi</span><span style="font-family:Verdana;"> population. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> We applied PTEN immunohistochemistry on 98 patients. Then, we applied next-generation sequencing to determine the genetic variations associated with the development of breast cancer and their correlations with clinicopathological variables. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">PTEN expression was significantly correlated with lymph node metastasis (LNM), tumor stage, lymphovascular invasion (LVI) </span><span style="font-family:Verdana;">and</span> <span style="font-family:Verdana;">triple negative</span><span style="font-family:
